Rationale for the use of structure-modifying drugs and agents in the treatment of osteoarthritis

Osteoarthritis and Cartilage

Volumn 12, Issue SUPLL., 2004, Pages 63-68

  Pelletier, Jean Pierre ^a  

^a NOTRE DAME HOSPITAL   (Canada)

Author keywords

Osteoarthritis; Pathophysiology; Therapeutic targets

Indexed keywords

ANTIRHEUMATIC AGENT; BIOLOGICAL FACTOR; CALCIUM; CARPROFEN; CHELATING AGENT; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE; CYTOKINE RECEPTOR; DOXYCYCLINE; GROWTH FACTOR; ICOSANOID; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA CONVERTING ENZYME INHIBITOR; MATRIX METALLOPROTEINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE P38; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; ZINC; METALLOPROTEINASE; NITRIC OXIDE;

ARTICLE; BIOSYNTHESIS; BONE ATROPHY; BONE METABOLISM; CARTILAGE; CARTILAGE CELL; CLINICAL TRIAL; DISEASE COURSE; DRUG POTENCY; DRUG SCREENING; DRUG SPECIFICITY; DRUG TARGETING; DRUG USE; HUMAN; NONHUMAN; OSTEOARTHRITIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SIDE EFFECT; SYNOVIUM; TISSUE STRUCTURE; TISSUE TYPES; BONE REMODELING; DRUG EFFECT; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANTIRHEUMATIC AGENTS; BONE REMODELING; CYTOKINES; HUMANS; METALLOPROTEASES; NITRIC OXIDE; OSTEOARTHRITIS; SIGNAL TRANSDUCTION;

EID: 1542541984     PISSN: 10634584     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.joca.2003.09.014     Document Type: Article

References (30)

1. Pelletier J.P. Martel-Pelletier J. Howell D.S. Etiopathogenesis of osteoarthritis In: Koopman W.J. (Ed.) Arthritis - Allied Conditions. A Textbook of Rheumatology 2001 2195-2245 Williams - Wilkins Baltimore
2. Martel-Pelletier J. Di Battista J.A. Lajeunesse D. Biochemical factors in joint articular tissue degradation in osteoarthritis In: Reginster J.Y. Pelletier J.P. Martel-Pelletier J. Henrotin Y. (Eds.) Osteoarthritis: Clinical and Experimental Aspects 1999 156-187 Springer-Verlag Berlin
3. Pelletier J.P. Reginster J.Y. The influence of tissular cross-talking on osteoarthritis progression: role of nonsteroidal antiinflammatory drugs Osteoarthritis Cartilage 7 1999 306-307
4. Pelletier J.P. Martel-Pelletier J. Abramson S.B. Osteoarthritis, an inflammatory disease: potential implication for the selection of new therapeutic targets Arthritis Rheum 44 2001 1237-1247
5. Lajeunesse D. Hilal G. Pelletier J.P. Martel-Pelletier J. Subchondral bone morphological and biochemical alterations in osteoarthritis Osteoarthritis Cartilage 7 1999 321-322
6. Moldovan F. Pelletier J.P. Hambor J. Cloutier J.M. Martel-Pelletier J. Collagenase-3 (matrix metalloprotease 13) is preferentially localized in the deep layer of human arthritic cartilage in situ: In vitro mimicking effect by transforming growth factor beta Arthritis Rheum 40 1997 1653-1661
7. Ayral X. Pickering E.H. Woodworth T.G. Mackillop N. Dougados M. Synovitis predicts the arthroscopic progression of medial tibiofemoral knee osteoarthritis Osteoarthritis Cartilage 9 2001 S2
8. Amin A.R. Abramson S.B. The role of nitric oxide in articular cartilage breakdown in osteoarthritis Curr Opin Rheumatol 10 1998 263-268
9. Firestein G.S. Manning A.M. Signal transduction and transcription factors in rheumatic disease Arthritis Rheum 42 1999 609-621
10. Dhillon A.S. Kolch W. Untying the regulation of the Raf-1 kinase Arch Biochem Biophys 404 2002 3-9
11. Caron J.P. Fernandes J.C. Martel-Pelletier J. Tardif G. Mineau F. Geng C. et al. Chondroprotective effect of intraarticular injections of interleukin-1 receptor antagonist in experimental osteoarthritis: suppression of collagenase-1 expression Arthritis Rheum 39 1996 1535-1544
12. Fernandes J.C. Martel-Pelletier J. Pelletier J.P. Gene therapy for osteoarthritis: new perspectives for the twenty-first century Clin Orthop 379 Suppl 2000 S262-S272
13. Fernandes J.C. Tardif G. Martel-Pelletier J. Lascau-Coman V. Dupuis M. Moldovan F. et al. In vivo transfer of interleukin-1 receptor antagonist gene in osteoarthritic rabbit knee joints: Prevention of osteoarthritis progression Am J Pathol 154 1999 1159-1169
14. Pelletier J.P. Caron J.P. Evans C.H. Robbins P.D. Georgescu H.I. Jovanovic D. et al. In vivo suppression of early experimental osteoarthritis by IL-Ra using gene therapy Arthritis Rheum 40 1997 1012-1019
15. Jiang Y. Genant H.K. Watt I. Cobby M. Bresnihan B. Aitchison R. et al. A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores Arthritis Rheum 43 2000 1001-1009
16. Saha N. Moldovan F. Tardif G. Pelletier J.P. Cloutier J.M. Martel-Pelletier J. Interleukin-1ß-converting enzyme/Caspase-1 in human osteoarthritic tissues: Localization and role in the maturation of IL-1ß and IL-18 Arthritis Rheum 42 1999 1577-1587
17. Badger A.M. Griswold D.E. Kapadia R. Blake S. Swift B.A. Hoffman S.J. et al. Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritis Arthritis Rheum 43 2000 175-183
18. Pelletier J.P. Moldovan F. Fernandes J.C. Schrier D. Flory C. Martel-Pelletier J. In vivo selective inhibition of ERK 1/2 in rabbit experimental osteoarthritis is associated with a reduction in the progression of articular tissue structural changes and metalloprotease inhibition Arthritis Rheum 44 2001 S305
19. Fahmi H. Di Battista J.A. Pelletier J.P. Mineau F. Ranger P. Martel-Pelletier J. Peroxisome proliferator-activated receptor gamma activators inhibit interleukin-1beta-induced nitric oxide and matrix metalloproteinase 13 production in human chondrocytes Arthritis Rheum 44 2001 595-607
20. Martel-Pelletier J. Pelletier J.P. Wanted-the collagenase responsible for the destruction of the collagen network in human cartilage! Br J Rheumatol 35 1996 818-820
21. Martel-Pelletier J. Tardif G. Fernandes J.C. Pelletier J.P. Metalloproteases and their modulation as treatment in osteoarthritis In: Tsokos G.C. (Ed.) Molecular Rheumatology 2000 499-514 Humana Press Inc Totowa, New Jersey
22. Yu Jr. L.P. Smith Jr. G.N. Brandt K.D. Myers S.L. O'Connor B.L. Brandt D.A. Reduction of the severity of canine osteoarthritis by prophylactic treatment with oral doxycycline Arthritis Rheum 35 1992 1150-1159
23. Pelletier J.P. Jovanovic D. Fernandes J.C. Manning P.T. Connor J.R. Currie M.G. et al. Reduced progression of experimental osteoarthritis in vivo by selective inhibition of inducible nitric oxide synthase Arthritis Rheum 41 1998 1275-1286
24. Blanco F.J. Ochs R.L. Schwarz H. Lotz M. Chondrocyte apoptosis induced by nitric oxide Am J Pathol 146 1995 75-85
25. Pelletier J.P. Jovanovic D.V. Lascau-Coman V. Fernandes J.C. Manning P.T. Connor J.R. et al. Selective inhibition of inducible nitric oxide synthase reduces progression of experimental osteoarthritis in vivo: possible link with the reduction in chondrocyte apoptosis and caspase 3 level Arthritis Rheum 43 2000 1290-1299
26. Pelletier J.P. Lascau-Coman V. Jovanovic D. Fernandes J.C. Manning P. Currie M.G. et al. Selective inhibition of inducible nitric oxide synthase in experimental osteoarthritis is associated with reduction in tissue levels of catabolic factors J Rheumatol 26 1999 2002-2014
27. Notoya K. Jovanovic D.V. Reboul P. Martel-Pelletier J. Mineau F. Pelletier J.P. The induction of cell death in human osteoarthritis chondrocytes by nitric oxide is related to the production of prostaglandin E2 via the induction of cyclooxygenase-2 J Immunol 165 2000 3402-3410
28. Lajeunesse D. The role of bone in the treatment of osteoarthritis Osteoarthritis Cartilage 2004
29. Burr D.B. Anatomy and physiology of the mineralized tissues: Role in the pathogenesis of osteoarthrosis Osteoarthritis Cartilage 2004
30. Pelletier J.P. Lajeunesse D. Jovanovic D.V. Lascau-Coman V. Jolicoeur F.C. Hilal G. et al. Carprofen simultaneously reduces progression of morphological changes in cartilage and subchondral bone in experimental dog osteoarthritis J Rheumatol 27 2000 2893-2902